Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Down 38.0% in June

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 20,835 shares, a decline of 38.0% from the June 15th total of 33,610 shares. Based on an average daily trading volume, of 77,001 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Curanex Pharmaceuticals Price Performance

CURX opened at $0.21 on Friday. Curanex Pharmaceuticals has a 12-month low of $0.20 and a 12-month high of $9.18. The stock has a market capitalization of $5.83 million and a PE ratio of -0.76. The firm’s fifty day moving average price is $0.29 and its 200 day moving average price is $0.35.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter.

Institutional Trading of Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the third quarter, according to its most recent filing with the SEC. The fund purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.